Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise With Appointment of Mark Chang

Contact Veristat Now


Request A Proposal

Contact Us

June 15, 2016

Appoints Mark Chang as Senior Vice President of Strategic Statistical Consulting

 

Mark Chang

SOUTHBOROUGH, MA – June 15, 2016Veristat, a full service Clinical Research Organization (CRO), announced that it has strengthened its statistical consulting and adaptive design expertise with the appointment of Mark Chang, PhD to the newly created position of Senior Vice President of Strategic Statistical Consulting.   Dr. Chang will help clients evaluate and implement strategic, operational and technical efficiencies to advance products through the clinical trial and regulatory submission process.

Veristat is thrilled to welcome such an esteemed clinical research and statistical expert to Veristat,” stated John Balser, PhD, President of Veristat. “Mark will provide Veristat’s clients with the intellectual leadership to optimize their clinical development plans, trial designs and regulatory submission strategies. His experience with designing and implementing both simple and complex adaptive design trials is unmatched in the industry.

Dr. Chang joins Veristat with more than 20 years of experience as a statistician at both biopharmaceutical firms and CROs, including AMAG Pharmaceuticals, Millenium/Takeda Pharmaceuticals, PAREXEL and MTRA. He is experienced with NDA submissions and working collaboratively with the regulatory agencies throughout the clinical trial and submission process.  Dr. Chang is also an adaptive design expert, having authored and co-authored dozens of books and peer- reviewed journal publications on adaptive design methodologies and implementation in clinical trials.

In addition, Dr. Chang is a fellow of the American Statistical Association and an adjunct professor of Biostatistics at Boston University. He is a co-founder of the International Society for Biopharmaceutical Statistics, co-chair of the Biotechnology Industry Organization (BIO) Adaptive Design Working Group, and a member of the Multiregional Clinical Trial (MRCT) Expert Group.  Throughout his career, he has frequently held advisory posts for numerous industry committees and served as an associate editor for many peer-reviewed publications.  He has given over 50 lectures, short courses, and invited speeches at national and international conferences and has been invited twice to present at the US Food and Drug Administration.

Dr. Chang received his Ph.D. in Civil Engineering and his Masters of Science in Biostatistics at the University of Massachusetts in Amherst, MA.   He also received his Masters of Science and Bachelors of Science degrees at Hohai University in Nanjing, China.

About Veristat:

Veristat is an innovative full-service, science-focused clinical research organization (CRO) with over 20 years of experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. Veristat offers comprehensive clinical development services, including biostatistics, statistical programming, medical writing, clinical monitoring, project management and data management, for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Due to Veristat’s unwavering commitment to scientific integrity, client focus and exceptional performance, long-lasting client relationships are our hallmark. For more information, please visit www.veristat.com.

Veristat Contact: Gillian Dellacioppa, Marketing Director gillian.dellacioppa@veristat.com or 508-306-6336